Prednisone for Ménière's Disease
Oral prednisone is not a first-line treatment for Ménière's disease, but intratympanic (IT) steroids may be offered to patients with active disease who have failed conservative management. The 2020 AAO-HNS guideline specifically addresses steroid therapy but focuses on IT delivery rather than oral administration 1.
Treatment Hierarchy for Ménière's Disease
The evidence-based approach follows a stepwise algorithm from least to most invasive 1:
First-Line Management
- Dietary modifications: Low-sodium diet (1500-2300 mg daily), limit alcohol and caffeine
- Diuretics: For fluid management
- Vestibular suppressants: Limited course for acute vertigo episodes 1
- Betahistine: Histamine analogue to increase inner ear vasodilation (where available)
Second-Line: Intratympanic Steroids
The guideline states clinicians may offer IT steroids to patients with active Ménière's disease 1. The evidence shows:
- Vertigo control: 85-90% improvement with IT steroids versus 57-80% with conventional therapy 1
- Hearing preservation: Lower risk of hearing loss (0-8%) compared to IT gentamicin (12.5-15.4%) 1
- Dosing regimens 1:
- Dexamethasone: 0.4-0.8 mL (4-24 mg/mL concentration) injected into middle ear
- Methylprednisolone: 0.4-0.8 mL (30-62.5 mg/mL concentration)
- Frequency: Single injection or up to 3-4 sessions every 3-7 days depending on response
Oral Prednisone: Limited Evidence
While one pilot study showed oral prednisone (0.35 mg/kg daily for 18 weeks) reduced vertigo frequency by 50% and duration by 30% 2, this is low-quality evidence from a small trial (n=16). The 2023 Cochrane review concluded that evidence for systemic corticosteroids in Ménière's disease is "very low-certainty" 3.
The AAO-HNS guideline does not recommend oral steroids as standard therapy 1. Survey data shows oral steroids (prednisone, dexamethasone) are used more commonly by high-volume practitioners, but this reflects practice patterns rather than evidence-based recommendations 4.
When Oral Prednisone Might Be Considered
Based on general corticosteroid principles 5:
- Bilateral Ménière's disease with suspected autoimmune etiology 6
- Acute exacerbations when IT injection is not immediately available
- Dosing (if used): 5-60 mg daily depending on severity, administered in morning before 9 AM to minimize HPA axis suppression 5
- Duration: Shortest effective course, with gradual taper to avoid adrenal insufficiency 5
Critical Caveats
Common pitfalls to avoid:
- Don't use oral steroids as first-line: Dietary modification and diuretics should be tried first 1
- Monitor for steroid complications: Osteoporosis risk, hyperglycemia, hypertension, psychiatric effects 5
- Gradual withdrawal essential: Abrupt discontinuation can cause adrenal crisis 5
- Consider bone protection: Calcium, vitamin D, bisphosphonates if treatment ≥3 months anticipated 5
Third-Line Options (Refractory Disease)
If conservative measures and IT steroids fail 1:
- IT gentamicin: For patients with inadequate control, accepting risk of hearing loss
- Surgical options: Endolymphatic sac decompression, vestibular nerve section, labyrinthectomy
Bottom Line
Intratympanic steroids are the evidence-based steroid delivery method for Ménière's disease, not oral prednisone 1. The stepwise approach prioritizes dietary modification and diuretics first, reserves IT steroids for active disease, and considers oral steroids only in specific circumstances like bilateral disease with autoimmune features 1, 6. The quality of evidence for oral prednisone remains very low 3.